(function(){ var content_array=["

關于諾和諾德<\/b><\/p> \n

諾和諾德公司成立于1923年，是一家全球領先的生物制藥公司，總部位于丹麥。立足于在糖尿病領域的百年傳承，我們的使命是驅動改變，攜手戰勝嚴重慢性疾病。為達成這一目標，我們引領科研突破，擴大公司藥物可及性，并致力于預防及最終治愈疾病。諾和諾德在全球80個國家和地區擁有約7.84萬名員工，向全球約170個國家和地區提供產品和服務。諾和諾德<\/span>中國官方網站：http:\/\/www.novonordisk.com.cn<\/a><\/p> \n

免責聲明<\/b><\/p> \n

本新聞稿僅用于傳遞相關前沿科學信息和市場資訊。本新聞稿不構成對任何藥物或治療方案的推薦、推廣或廣告。讀者不應參考、依據或依賴本新聞稿的任何內容，作出購買、使用任何藥物或治療方案的任何決定。如讀者有藥物或治療方面的問題，請咨詢醫療衛生專業人士。<\/p> \n

本新聞稿含有關于諾和諾德產品的前瞻性信息，該等信息的有效性僅截至其發布日期。諾和諾德無義務就由于新信息、未來事件、事件進展或其他原因產生的任何變化對相關信息進行更新。對于因使用、依賴本新聞稿中包含的任何信息或任何信息遺漏而直接或間接產生的任何損失，諾和諾德不承擔任何責任。<\/p> \n

在轉發、使用或以其它方式處理本新聞稿中的信息前，相關行為人應負責確保其行為符合所有相關國家或司法管轄區的任何適用法律、法規和監管要求。任何由于引用、轉載、編輯或通過其它方式使用本新聞稿中所含信息而產生的一切直接或間接的后果，均由相關行為人自行承擔全部責任，諾和諾德不對此承擔任何責任。建議相關行為人在轉發、使用或以其它方式處理本新聞稿中的信息前審慎評估風險，必要時請咨詢專業法律人士的意見。<\/p> \n

特此聲明。<\/p> \n

\n \n \n \n
<noscript id="kgssg"><option id="kgssg"></option></noscript><optgroup id="kgssg"><wbr id="kgssg"></wbr></optgroup><optgroup id="kgssg"></optgroup>
<optgroup id="kgssg"><div id="kgssg"></div></optgroup>
<center id="kgssg"><div id="kgssg"></div></center>
<center id="kgssg"></center>
久久久亚洲欧洲日产国码二区

_______________________
參考文獻<\/b><\/span><\/p>

1.     Wilson L, Zhao Z, Divino V, et al<\/i>. Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice. Oral presentation at the European Society of Cardiology Congress 2025; 29 August–01 September 2025; IFEMA Madrid, Madrid, Spain.<\/span><\/p>

2.     World Heart Federation. World Heart Report 2023: Confronting the World's Number One Killer. Available at: https:\/\/world-heart-federation.org\/wp-content\/uploads\/World-Heart-Report-2023.pdf<\/a>. Last accessed: July 2025.<\/span><\/p>

3.     Haidar A and Horwich T. Obesity, Cardiorespiratory Fitness, and Cardiovascular Disease. Curr Cardiol Rep<\/i>. 2023;25:1565–1571.<\/span><\/p>

4.     Zizza C, Herring AH, Stevens J, et al.<\/i> Length of Hospital Stays Among Obese Individuals. Am J Public Health<\/i>. 2004;94:1587–1591.<\/span><\/p>

5.     Raisi-Estabragh Z, Kobo O, Mieres JH, et al.<\/i> Racial Disparities in Obesity-Related Cardiovascular Mortality in the United States: Temporal Trends From 1999 to 2020. J Am Heart Assoc<\/i>. 2023;12: e028409.<\/span><\/p>

6.     Collaborators GBDO, Afshin A, Forouzanfar MH, et al<\/i>. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med<\/i>. 2017;377:13–27.<\/span><\/p>

7.     Blonde L, Khunti K, Harris SB, et al<\/i>. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Adv Ther<\/i>. 2018;35:1763–1774.<\/span><\/p>

8.     Lincoff AM, Brown-Frandsen K, Colhoun HM, et al<\/i>. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med<\/i>. 2023;389:2221–2232.<\/span><\/p>

9.     Zhao Z, Song J, Faurby M, et al<\/i>. Lower Risk of MACE and All-Cause Death in Patients Initiated on Semaglutide 2.4 mg in Routine Clinical Care: Results from the SCORE Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World). Moderated poster presentation at the American College of Cardiology Scientific Session & Expo 2025; 29–31 March 2025; McCormick Place Convention Center, Chicago, US. Presentation 947-13.<\/span><\/p>

10.   Wegovy®<\/sup> Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/wegovy-epar-product-information_en.pdf<\/a>. Last accessed: August 2025.<\/span><\/p>

11.   Wegovy®<\/sup> Prescrib information. Avaialble at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215256s015lbl.pdf<\/a>. Last accessed: August 2025.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div>"]; $("#dvExtra").html(content_array[0]);})();